KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

PURPOSE: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti-EGFR targeted therapy (cetuximab or panitumumab). However, it remains uncertain w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ogino, Shuji, Meyerhardt, Jeffrey A., Irahara, Natsumi, Niedzwiecki, Donna, Hollis, Donna, Saltz, Leonard B., Mayer, Robert J., Schaefer, Paul, Whittom, Renaud, Hantel, Alexander, Benson, Al B., Goldberg, Richard M., Bertagnolli, Monica M., Fuchs, Charles S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2787689/
https://ncbi.nlm.nih.gov/pubmed/19934290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1570
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares